Biomarker testing through next-generation sequencing (NGS) technology has enabled precision oncology to deliver faster, cheaper, and more accurate tumor data. Results from NGS testing can help providers to diagnose cancer, personalize treatment, determine prognosis, or evaluate hereditary cancer risk. Identification of biomarker or driver variants can match patients to approved targeted therapies and clinical trials. This toolkit educates oncology nurses about NGS with a sample report, glossary of terms, and patient education.
This resource was produced by ONS and sponsored by Foundation Medicine.
The ONS Biomarker Database was developed as a clinical decision support (CDS) tool to bring the most recent biomarker advances to the point of care.